Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

MOUNTAIN VIEW, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) reported today financial results for the quarter and six month period ended June 30, 2008 and provided an update on the Company's progress with its product development candidates. The net loss for the quarter and six month period ended June 30, 2008, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $14.1 million and $28.7 million, respectively, compared to a net loss of $10.3 million and $21.2 million in the comparable periods in 2007. Alexza had consolidated cash, cash equivalents and marketable securities (including investments held by Symphony Allegro) at June 30, 2008 of $95.3 million.

"Alexza continues to make significant progress with our lead program, AZ-004 (Staccato(R) loxapine), which is being developed for the treatment of acute agitation in schizophrenic or bipolar disorder patients," said Thomas B. King, President and CEO of Alexza. "During the first seven months of 2008, we initiated and completed the dosing of our first AZ-004 Phase 3 clinical trial, and have initiated dosing of our second AZ-004 Phase 3 clinical trial. In addition, we had clinical readouts from clinical trials with AZ-104, AZ-007 and AZ-002. We are also scaling up our manufacturing, quality systems, regulatory affairs and commercial operations as we prepare for the future commercialization of AZ-004."

Financial Results - Periods Ended June 30, 2008 and 2007

GAAP operating expenses were $20.5 million and $39.7 million in the quarter and six month period ended June 30, 2008, compared to $14.2 million and $28.0 million for the comparable periods in 2007. The increases resulted primaril
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... (Nasdaq: THOR ), a world leader in device-based ... hearts, today announced that it will report its operating results ... 1. The company will hold a conference call ... all interested parties, at 1:30 p.m., Pacific Daylight Time (4:30 ...
... 2011 At the 5 ... in Barcelona, Spain (20-22 October 2011),   Merz Pharmaceuticals ... efficacy and safety of   XEOMIN ® ... Dystonia is a particularly debilitating condition ...
Cached Medicine Technology:Thoratec Schedules Third Quarter Conference Call, Webcast 2Merz research Shows Long-term Benefits for Patients With Dystonia 2Merz research Shows Long-term Benefits for Patients With Dystonia 3Merz research Shows Long-term Benefits for Patients With Dystonia 4
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
(Date:12/26/2014)... 2014 The US represents the largest market ... 2013, GlobalData’s forecast estimates that sales of branded therapies were ... to the high incidence of the disease, high drug treatment ... and China. Increased sales of CRC therapies over the forecast ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... , BEDFORD, Mass., July 13 Hologic, Inc. (Hologic ... leading developer, manufacturer and supplier of premium diagnostics, medical ... healthcare needs of women, today announced plans to release ... August 3, 2009 after market close. In conjunction with ...
... July 13 Long term care costs in Wyoming continue ... pressure on those in or near retirement. As a leader ... suite of insurance products to help people proactively plan for ... take advantage of a new program designed to simplify the ...
... WALTHAM, Mass., July 13 Decision Resources, one of the ... healthcare issues, finds that the rheumatoid arthritis (RA) drug market ... in 2008 to $385 million in 2013. This growth will ... to healthcare insurance, greater patient spending power and increased use ...
... , , , ... July 13 CareGuide, Inc., an emerging health management company, welcomes ... as Area Vice President of Sales. Both are located in Texas ... location. , , Julie Sizemore ( ...
... RATON, Fla., July 13 Laura E. Skellchock, M.D. at Integrative ... collagen filler for the correction of smile lines, to treat patients ... has been an avid Artefill user the past several years due ... , , "It,s the perfect ...
... Calif., July 13 Sit ,n Sleep, the mattress ... millions of Southern Californians, today launched a new campaign ... right mattress and improved sleep health and well-being. Widely-known ... in town, Sit ,n Sleep,s new strategic direction ...
Cached Medicine News:Health News:Hologic to Release Third Quarter Fiscal 2009 Operating Results on Monday, August 3, 2009 2Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 2Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 3Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 4Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 5Health News:China's Rheumatoid Arthritis Drug Market Will More than Double by 2013 2Health News:China's Rheumatoid Arthritis Drug Market Will More than Double by 2013 3Health News:CareGuide Adds New Management Team Members 2Health News:Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 2Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 3Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 4
Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
... Resolve Immersion Oil is a clear, ... throughout most of the UV-VIS spectrum. ... and high viscosity, is non-drying and ... of 1.5150. Resolve contains no PCBs, ...
Medicine Products: